Table 1 Study population baseline characteristics
Patient characteristics | n (%) | Patient characteristics | Mean ± sd |
|---|---|---|---|
Male | 42 (49.4%) | Age (years) | 60 ± 10 |
Caucasian | 85 (100%) | Body mass index (Kg/m2) | 30.9 ± 4.5 |
Current smoker | 8 (9.4%) | Waist circunference (cm) | 104.4 ± 9.2 |
Ex-smoker | 17 (20%) | Duration of diabetes (years) | 13 ± 9 |
Metabolic syndrome | 59 (69.4%) | HbA1c (%) | 8.2 ± 1.7 |
Hypertension | 79 (92.9%) | Serum creatinine (μmol/L) | 69 ± 16.7 |
Dyslipidemia | 68 (80%) | GFR (mL/min/1.73m2) | 98.9 ± 25.7 |
Family history of CAD | 8 (9.4) | Urine microalbumin (mg/24h) | 61.4 ± 132.4 |
Insulin treatment | 42 (49.4%) | Total cholesterol (mmol/L) | 5 ± 1.3 |
Oral hypoglycaemic therapy | 73 (85.9%) | LDL cholesterol (mmol/L) | 3.1 ± 1 |
Statins | 45 (52.9%) | HDL cholesterol (mmol/L) | 1.2 ± 0.4 |
ACE inhibitor/ARB | 31 (36.1%) | Triglycerides (mmol/L) | 1.9 ± 1.3 |
Antiplatelets | 69 (81.2%) | C-reactive protein (mg/dL) | 0.38 ± 0.35 |
Diabetic neuropathy | 19 (24.1%) | Framingham | 21 ± 12 |
Diabetic retinopathy/nephopaty | 30 (38%) |